search
Back to results

AI-09 In Subjects With Glabellar Lines, GL-101

Primary Purpose

Glabellar Frown Lines

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AI-09
Vehicle
Sponsored by
Eirion Therapeutics Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glabellar Frown Lines

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • able to understand and give written informed consent
  • willingness to have their pictures taken
  • 20 - 70 years of age
  • moderate to severe glabellar lines (IGA 2-3) on contraction
  • moderate to severe glabellar lines (SSA 2-3) on contraction
  • mild to moderate glabellar lines wrinkles (IGA 0-1) at rest
  • willingness to refrain from the use of facial fillers, retinoids, Botox, laser treatments, or any product affecting skin remodeling or that might cause an active dermal response during the course of the study
  • female subjects of child-bearing potential must have a negative urine pregnancy test and be non-lactating at the Baseline visit
  • female subjects of child-bearing potential must utilize one of the following methods of birth control throughout the study: IUD, diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 4 months prior to Baseline and has not changed the brand within this period), or patch, injectable, implantable, or vaginal ring contraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy)
  • subjects should be in good general health as determined by the investigator and free of any disease that may interfere with study evaluations or the Investigational Product

Exclusion Criteria:

  • the inability to substantially lessen glabellar lines by physically spreading them apart
  • excessive weakness or atrophy in the target muscle(s)
  • eyelid ptosis
  • presence or history of "dry eye"
  • history of periocular surgery, brow lift or related procedures, or deep dermal scarring
  • concurrent or recent (within the last 6 months) use of any other botulinum toxin drug product anywhere in the body
  • history of immunization or hypersensitivity to any botulinum toxin serotype
  • history of non-response to any prior botulinum toxin treatments
  • anticipated need for treatment with botulinum toxin of any serotype for a reason during the trial (other than the investigational treatment)
  • any medical condition that may put the subject at increased risk with exposure to botulinum toxin including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
  • pregnancy or lactation
  • application of any topical prescription medication to the treatment area within 14 days prior to treatment
  • subjects on clinically significant, concomitant drug therapy
  • participation in another investigational drug trial or receiving any investigational treatment(s) within 30 days of Baseline
  • alcohol or drug abuse within the past 3 years
  • psychiatric disease interfering with the subject's ability to give informed consent
  • refusal or inability to comply with the requirements of the protocol for any reason

Sites / Locations

  • Eirion Research SiteRecruiting
  • Eirion Research SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

AI-09 Dose 1

Vehicle Dose 1

AI-09 Dose 2

Vehicle Dose 2

AI-09 Dose 3

Vehicle Dose 3

AI-09 Dose 4

Vehicle Dose 4

AI-09 Dose 5

Vehicle Dose 5

AI-09 Dose 6

Vehicle Dose 6

Arm Description

Dose 1 of botulinum toxin, Type A, intramuscular injection, administered once at baseline

Vehicle, intramuscular injection, administered once at baseline

Dose 2 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline

Vehicle, intramuscular injection, administered once at baseline

Dose 3 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline

Vehicle, intramuscular injection, administered once at baseline

Dose 4 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline

Vehicle, intramuscular injection, administered once at baseline

Dose 5 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline

Vehicle, intramuscular injection, administered once at baseline

Dose 6 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline

Vehicle, intramuscular injection, administered once at baseline

Outcomes

Primary Outcome Measures

Investigators Global Assessment (IGA)
Investigators Global Assessment. Glabellar Line Severity scale where severity is scored between 0-4 (0=absent; 4=severe).

Secondary Outcome Measures

Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score
Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Glabellar Line Severity scale (GLS), where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments.

Full Information

First Posted
September 27, 2022
Last Updated
September 15, 2023
Sponsor
Eirion Therapeutics Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05565950
Brief Title
AI-09 In Subjects With Glabellar Lines, GL-101
Official Title
A Phase 1/2 Study to Establish An Initial Therapeutic Range and Safety Data for AI-09 in the Treatment of Glabellar Lines
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 3, 2022 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eirion Therapeutics Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
AI-09 In Subjects with Glabellar Lines
Detailed Description
A Phase 1/2, multicenter, out-patient, prospectively randomized, double-blind, vehicle-controlled study to establish an initial therapeutic range for AI-09 in the treatment of glabellar lines and provide initial data regarding its potential safety.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glabellar Frown Lines

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AI-09 Dose 1
Arm Type
Experimental
Arm Description
Dose 1 of botulinum toxin, Type A, intramuscular injection, administered once at baseline
Arm Title
Vehicle Dose 1
Arm Type
Placebo Comparator
Arm Description
Vehicle, intramuscular injection, administered once at baseline
Arm Title
AI-09 Dose 2
Arm Type
Experimental
Arm Description
Dose 2 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Arm Title
Vehicle Dose 2
Arm Type
Placebo Comparator
Arm Description
Vehicle, intramuscular injection, administered once at baseline
Arm Title
AI-09 Dose 3
Arm Type
Experimental
Arm Description
Dose 3 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Arm Title
Vehicle Dose 3
Arm Type
Placebo Comparator
Arm Description
Vehicle, intramuscular injection, administered once at baseline
Arm Title
AI-09 Dose 4
Arm Type
Experimental
Arm Description
Dose 4 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Arm Title
Vehicle Dose 4
Arm Type
Placebo Comparator
Arm Description
Vehicle, intramuscular injection, administered once at baseline
Arm Title
AI-09 Dose 5
Arm Type
Experimental
Arm Description
Dose 5 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Arm Title
Vehicle Dose 5
Arm Type
Placebo Comparator
Arm Description
Vehicle, intramuscular injection, administered once at baseline
Arm Title
AI-09 Dose 6
Arm Type
Experimental
Arm Description
Dose 6 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
Arm Title
Vehicle Dose 6
Arm Type
Placebo Comparator
Arm Description
Vehicle, intramuscular injection, administered once at baseline
Intervention Type
Biological
Intervention Name(s)
AI-09
Intervention Description
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Intervention Type
Biological
Intervention Name(s)
Vehicle
Intervention Description
Vehicle Formulation
Primary Outcome Measure Information:
Title
Investigators Global Assessment (IGA)
Description
Investigators Global Assessment. Glabellar Line Severity scale where severity is scored between 0-4 (0=absent; 4=severe).
Time Frame
18 Weeks (26 Weeks for Cohorts 4, 5 & 6)
Secondary Outcome Measure Information:
Title
Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score
Description
Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Glabellar Line Severity scale (GLS), where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments.
Time Frame
Week 1, 2, 4, 8, 12, 18 (Week 26 assessments for Cohorts 4, 5 & 6)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: able to understand and give written informed consent willingness to have their pictures taken 20 - 70 years of age moderate to severe glabellar lines (IGA 2-3) on contraction moderate to severe glabellar lines (SSA 2-3) on contraction none to mild glabellar lines wrinkles (IGA 0-1) at rest willingness to refrain from the use of facial fillers, retinoids, Botox, laser treatments, or any product affecting skin remodeling or that might cause an active dermal response during the course of the study female subjects of child-bearing potential must have a negative urine pregnancy test and be non-lactating at the Baseline visit female subjects of child-bearing potential must utilize one of the following methods of birth control throughout the study: IUD, diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 4 months prior to Baseline and has not changed the brand within this period), or patch, injectable, implantable, or vaginal ring contraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy) subjects should be in good general health as determined by the investigator and free of any disease that may interfere with study evaluations or the Investigational Product Exclusion Criteria: the inability to substantially lessen glabellar lines by physically spreading them apart excessive weakness or atrophy in the target muscle(s) eyelid ptosis presence or history of "dry eye" history of periocular surgery, brow lift or related procedures, or deep dermal scarring concurrent or recent (within the last 6 months) use of any other botulinum toxin drug product anywhere in the body history of immunization or hypersensitivity to any botulinum toxin serotype history of non-response to any prior botulinum toxin treatments anticipated need for treatment with botulinum toxin of any serotype for a reason during the trial (other than the investigational treatment) any medical condition that may put the subject at increased risk with exposure to botulinum toxin including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function pregnancy or lactation application of any topical prescription medication to the treatment area within 14 days prior to treatment subjects on clinically significant, concomitant drug therapy participation in another investigational drug trial or receiving any investigational treatment(s) within 30 days of Baseline alcohol or drug abuse within the past 3 years psychiatric disease interfering with the subject's ability to give informed consent refusal or inability to comply with the requirements of the protocol for any reason
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick Murphy
Phone
4138210022
Email
ctgov@clinicalresearchmgt.com
Facility Information:
Facility Name
Eirion Research Site
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33432
Country
United States
Individual Site Status
Recruiting
Facility Name
Eirion Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33137
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

AI-09 In Subjects With Glabellar Lines, GL-101

We'll reach out to this number within 24 hrs